Bio-Cancer Treatment International Limited   Report issue

For profit Phase 1 Phase 2
Founded: Hong Kong Hong Kong (2000)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2008
NCT00988195
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

capecitabine (xeloda) (1 trial)

oxaliplatin (eloxatin) (1 trial)

pegylated arginine deiminase (7 trials)

Drugs in Phase 1 Trials (1)

doxorubicin (Doxil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 4